Skip to main content
. Author manuscript; available in PMC: 2010 Aug 1.
Published in final edited form as: Hepatology. 2009 Aug;50(2):622–629. doi: 10.1002/hep.23025

Figure 1. CAR is activated in STZ-induced type 1 diabetic mice and drug clearance is enhanced.

Figure 1

(A) Wild type and CAR-/- mice (n=5) were treated with or without STZ for 7 days and subgroups of diabetic mice were treated with insulin for 7 days. Blood glucose levels were measured on indicated days. (B) Liver total RNA was isolated from mice of different treatments and equal amounts of RNA were pooled from individual mice. Northern blot was performed with indicated probes. (C) Zoxazolamine was dosed to non-diabetic mice, diabetic mice and diabetic mice with insulin treatment. Paralysis time was compared in each group. (**p < 0.01).